However, both the liver tumor weight and the ratio of liver to mice body weight were significantly reduced in the experiment group, indicating the synergistic anti-HCC activity of the combination of STAT3 pathway deficiency and PD-1 checkpoint-blockade (Fig. 7h). The gene discussed is STAT3; the disease is hepatocellular carcinoma.